��ҽ�ƴ�ѧ������������ҽԺ, a. ҩ�²�; b.������Σ��֢ҽѧ��,���� 100020
Effectiveness of Pharmacist-Participated Warfarin Anticoagulation Management on Patients with Pulmonary Embolism
HOU Ke-lua, YANG Yuan-huab, WANG Zi-huia, GONG Juan-nib, KUANG Tu-guangb, CUI Xiang-lia*, LIU Li-honga*
a. Department of Pharmacy; b. Department of Respirology and Critical Medicine, Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China
ժҪĿ�� �����ٴ�ҩʦͨ��������ҩ�������������ҩ��ѯ��,�����˨�����߿������ƹ����Ч�������� ��2015��3����2017��4���ڱ�������ҽԺ������סԺ�ķ�˨�����߹���204��Ϊ�о�����,�Ƚ�ҩʦ������(��Ԥ��)������δ����ҩʦ������(������)INR��Ŀ�귶Χʱ��İٷֱ�(the percentage of INRs within the therapeutic range, TTR)��INR������Χ��ʱ��ٷֱ�(the percentage of INRs within the expanded range, TER)��INR�����ʱ�䡢��Ѫ�¼����ٴ�סԺ�ʼ���������ʡ���� ��Ԥ���TTR��TER�ֱ�Ϊ(70.89��26.02)%��(87.71��20.01)%,INR������������ڶ������(47.79��22.31)%��(71.23��21.47)%(P=0.000);��Ԥ���INR�����ʱ��Ϊ(27.48��12.81)d,�϶�����(43.35��13.65)d����������(P=0.000)�������鼰��Ԥ�黼�ߵ��ܳ�Ѫ�¼�(41.96% vs 29.35%,P=0.062)�����س�Ѫ�¼�(3.57% vs 2.17%,P=0.864)������Ѫ�¼�(38.39% vs 27.17%,P=0.091),�������ͳ��ѧ���塣��Ԥ�黼��Ժ��ļ����������������ڶ�����(9.82% vs 1.09%,P=0.008),���黼���ٴ���Ժ�������Բ���(8.04% vs 2.17%,P=0.125)������ �ٴ�ҩʦ�����˨�����߿������ƹ���ɰ������߸����ɵؼ��INR,���INR�����,���ٳ�Ժ��ļ������Ƶ�Ρ�
Abstract��OBJECTIVE To evaluate the effectiveness of pharmacist-participated warfarin anticoagulation management by patient education and medication consultation on patients with pulmonary embolism(PE). METHODS A total of 204 PE patients were hospitalized in respiratory wards from March 2015 to April 2017 enrolled eventually. Evaluation endpoints including the percentage of INRs within the therapeutic range(TTR), the percentage of INRs within the expanded range(TER), INR recall intervals, bleeding events, emergency department visits and hospitalizations related to anticoagulation therapy. RESULTS TTR and TER of intervention group were(70.89��26.02)% and(87.71��20.01)% respectively, which were both significantly higher than(47.79��22.31)% and(71.23��21.47)% in control group(P=0.000). INR recall intervals were(27.48��12.81) d versus(43.35��13.65) d (P=0.000). There were no significant differences between two groups in total bleeding events(41.96% vs 29.35%, P=0.062), minor bleeding events(38.39% vs 27.17%, P=0.091) and major bleeding events(3.57% vs 2.17%, P=0.864). And a significantly decreased in emergency department visits of intervention group(9.82% vs 1.09%, P=0.008), whereas no difference was observed in hospitalizations(8.04% vs 2.17%, P=0.125). CONCLUSION Clinical pharmacists participated in anticoagulation management of pulmonary embolism patients, which helped patients to monitor INRs more regularly, INR controlling better and decrease frequency of emergency department visits.
����¶, ���»�, ���ӻ�, ������, ������, ������, ������. �ٴ�ҩʦ�����˨�����߿������ƹ����Ч������[J]. �й�ҩѧ��־, 2018, 53(8): 646-651.
HOU Ke-lu, YANG Yuan-hua, WANG Zi-hui, GONG Juan-ni, KUANG Tu-guang, CUI Xiang-li, LIU Li-hong. Effectiveness of Pharmacist-Participated Warfarin Anticoagulation Management on Patients with Pulmonary Embolism. Chinese Pharmaceutical Journal, 2018, 53(8): 646-651.
HEIT J A. The epidemiology of venous thromboembolism in the community[J]. Arterioscler Thromb Vasc Biol, 2008,28(3):370-372.
[2]
HARPER P, HARPER J, HILL C. An audit of anticoagulant management to assess anticoagulation control using decision support software[J]. BMJ Open, 2014,4(9):e005864.
[3]
CHOE H M, KIM J S, CHOI K E, et al. Implementation of the first pharmacist-managed ambulatory care anticoagulation clinic in South Korea[J]. Am J Health Syst Pharm, 2002,59(9):872-874.
[4]
CHIQUETTE E, AMATO M G, BUSSEY H I. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs[J]. Arch Intern Med, 1998,158(15):1641-1647.
[5]
CHUA W B, CHEEN H H, KONG M C, et al. Modelling the cost-effectiveness of pharmacist-managed anticoagulation service for older adults with atrial fibrillation in Singapore[J]. Int J Clin Pharm, 2016,38(5):1230-1240.
[6]
HOU K L, YANG H, YE Z K, et al. Effectiveness of pharmacist-led anticoagulation management on clinical outcomes: a systematic review and Meta-analysis[J]. J Pharm Pharm Sci, 2017,20(1):378-396.
[7]
ZHANG Z, LUO M L, TIAN M, et al. Investigation and analysis on the current situation of warfarin usage in patients receiving anticoagulant therapy[J]. Clin Hosp Pharm J(�й�ҽԺҩѧ��־),2014,34(2):127-130.
[8]
ROSENDAAL F R, CANNEGIETER S C, VAN DER MEER F J, et al. A method to determine the optimal intensity of oral anticoagulation therapy[J]. Thromb Haemost, 1993,69(3):236-239.
[9]
SCHULMAN S, KEARON C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients[J]. J Thromb Haemost, 2005,3(4):692-694.
[10]
KONSTANTINIDES S V, TORBICKI A, AGNELLI G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism[J]. Eur Heart J, 2014,35(43):33033-33069.
[11]
KEARON C, AKL E A, OENELAS J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report[J]. Chest, 2016,149(2):315-352.
[12]
PIAZZA G, GOLDHABER S. Chronic thromboembolic pulmonary hypertension[J]. N Engl J Med, 2011,364(4):351-360.
[13]
DALEN J E, ALPERT J S. Natural history pf pulmonary embolism[J]. Prog Cardiov Dis, 1975,17(4):259-270.
[14]
NORDSTROM B L, EVANS M A, MURPHY B R, et al. Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary embolism patients treated with warfarin[J]. Curr Med Res Opin, 2015,31(3):439-447.
[15]
TRAN H A, CHUNILAL S D, HARPER P L, et al. An update of consensus guidelines for warfarin reversal[J]. Med J Aust, 2013,198(4):198-199.
[16]
VEEGER N J, PIERSMA-WICHERS M, TIJSSEN J G, et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2 300 consecutive patient with venous thromboembolism[J]. Br J Haematol, 2005,128(4):513-519.
[17]
CONNOLLY S J, POGUE J, EIKEBOOM J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range[J]. Circulation, 2008,118(20):2029-2037.
[18]
DING Z, WANG Y, PAN W F, et al. Establishment and prospect of anticoagulation clinic[J]. Clin Med J(�ٴ�ҩ������ѧ��־),2016,14(2): 40-43.
[19]
ZHOU L F, XIANG Q, WANG Z N, et al. A case study of pharmaceutical care on combined use of anticoagulants and anti-tuberculosis drugs[J]. Clin Pharm J(�й�ҩѧ��־), 2016,51(19):1706-1709.
[20]
CUI X L, WANG S H, LI J Y, et al. Application of case based study method in teaching practice of clinical pharmacist[J]. Chin J Clin Pharmacol(�й��ٴ�ҩ��ѧ��־),2017,33(7):659-661.
[21]
HOLBROOK A, SCHULMAN S, WITT D M, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2012,141(2 suppl):e152S-e184S.
[22]
PORTER A L, MARGOLIS A R, SCHOEN R R, et al. Use of an extended INR follow-up interval for veteran patients in an anticoagulation clinic[J]. J Thromb Haemost,2017,43(3):318-325.
[23]
CARRIS N W, SPINELLI A, PIERINI D, et al. Feasibility of extended-interval follow-up for patients receiving warfarin[J]. Cardiov Ther, 2015,33(3):98-103.
[24]
NAKAMURA M, MIYATA T, OZEKI Y, et al. Current venous thromboembolism management and outcomes in Japan[J]. Circ J, 2014,78(3):708-717.
[25]
SAOKAEW S, SAPOO U, NATHISUWAN S, et al. Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand[J]. Int J Clin Pharm, 2012,34(1):105-112.
[26]
VERRET L, COUTURIER J, ROZEN A, et al. Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial[J]. Pharmacotherapy, 2012,32(10):871-879.
[27]
BUNGARD T J, GARDNER L, ARCHER S L, et al. Evaluation of a pharmacist-managed anticoagulation clinic: improving patient care[J]. Open Med, 2009,3(1):e16-e21.
2018, Vol. 53 
